Ar­ray shows off the pos­i­tive BEA­CON CRC da­ta that helped spur Pfiz­er's $11.4B buy­out of­fer

In­ves­ti­ga­tors took cen­ter stage at a sci­en­tif­ic con­fer­ence to­day to tout the pos­i­tive da­ta from the BEA­CON CRC tri­al of Ar­ray’s BRAF/MEK triplet for drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER